Keyphrases
9-ING-41
12%
Adult T-cell Leukemia
12%
Apoptosis
37%
ATP-competitive Inhibitors
12%
Cancer Activity
12%
CDK4/6 Inhibitor Palbociclib
12%
Cell Cycle Progression
12%
Chromosome Alignment
12%
Chromosome Missegregation
12%
Clinical Trial Data
12%
Clinical Trial Design
12%
Clinical Trials
12%
Clinically Significant
12%
Combination Treatment
12%
Cytotoxic Chemotherapy
12%
Cytotoxic Effect
12%
Cytotoxicity
100%
DNA Damage
25%
Drug-induced
12%
Early Phase Clinical Trials
12%
Elraglusib
100%
Genotoxicity
12%
Glycogen Synthase Kinase 3 (GSK3)
100%
Glycogen Synthase kinase-3 Inhibitors
37%
IC50
12%
Kinetochore
12%
Lymphoma Cells
12%
Mechanism of Action
12%
Melanoma Treatment
12%
Microtubule Depolymerization
12%
Microtubule Destabilization
100%
Microtubule Destabilizer
12%
Mitotic Arrest
25%
Mitotic Slippage
12%
Multiple Cancer Types
12%
Multiple Tumors
12%
Ongoing Clinical Trials
12%
Orphan Drug Status
12%
Pan-cancer
12%
Pancreatic Cancer
12%
Randomized Phase II Trial
12%
Response Predictors
12%
Small Molecules
12%
Treatment Information
12%
Tumor Subtype
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adenosine Triphosphate
16%
Biological Marker
16%
Clinical Trial
50%
Clinical Trial Design
16%
Competitive Inhibitor
16%
Cytotoxic Chemotherapy
16%
Cytotoxicity
100%
Genotoxicity
16%
Glycogen Synthase Kinase 3
100%
Glycogen Synthase Kinase 3 Inhibitor
50%
IC50
16%
Malignant Neoplasm
16%
Melanoma
16%
Multiple Cancer
33%
Neoplasm
33%
Orphan Drug
16%
Palbociclib
16%
Pancreas Cancer
16%
Preclinical Study
16%
Side Effect
16%
T Cell Leukemia
16%